Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

A method for producing a cyclic carbonate represented by the following formula (1): ##STR00001##
wherein X.sup.1 and X.sup.2 are the same as or different from each other, and are each a hydrogen atom, a fluorine atom, or a monovalent organic group; and R is an organic group containing one or more carbon-carbon unsaturated bonds. The method includes reacting an unsaturated cyclic carbonate represented by the following formula (A): ##STR00002##
wherein X.sup.1 and X.sup.2 are defined as described above, and an alcohol represented by the formula (B): R—OH, wherein R is defined as described above, or an alkoxide thereof in the presence of a base, or reacting the unsaturated cyclic carbonate and the alkoxide. Also disclosed is a method for producing a cyclic carbonate.

A method for producing a cyclic carbonate represented by the following formula (1): ##STR00001##
wherein X.sup.1 and X.sup.2 are the same as or different from each other, and are each a hydrogen atom, a fluorine atom, or a monovalent organic group; and R is an organic group containing one or more carbon-carbon unsaturated bonds. The method includes reacting an unsaturated cyclic carbonate represented by the following formula (A): ##STR00002##
wherein X.sup.1 and X.sup.2 are defined as described above, and an alcohol represented by the formula (B): R—OH, wherein R is defined as described above, or an alkoxide thereof in the presence of a base, or reacting the unsaturated cyclic carbonate and the alkoxide. Also disclosed is a method for producing a cyclic carbonate.

Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

In one aspect, the invention relates to compounds having the formula:

##STR00001## where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

In one aspect, the invention relates to compounds having the formula:

##STR00001## where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.